Abrdn Life Sciences Investors Balance Sheet Health
Financial Health criteria checks 2/6
Abrdn Life Sciences Investors has a total shareholder equity of $422.6M and total debt of $9.3M, which brings its debt-to-equity ratio to 2.2%. Its total assets and total liabilities are $432.7M and $10.0M respectively.
Key information
2.2%
Debt to equity ratio
US$9.33m
Debt
| Interest coverage ratio | n/a |
| Cash | US$822.00 |
| Equity | US$422.65m |
| Total liabilities | US$10.04m |
| Total assets | US$432.69m |
Recent financial health updates
No updates
Recent updates
HQL: Hold Your Investments In This Healthcare CEF For Strong, Steady Yield
Sep 27HQL: 13% Discount Creates An Opportunity
Jun 29Tekla Life Sciences raises dividend by 6.5% to $0.33
Feb 15Tekla Life Sciences declines quarterly dividend by -11.4% to $0.31/share
Nov 16Tekla Life Sciences Investors: 10% Yield And Trading 10.5% Below NAV
Oct 23HQL: A Biotechnology Equity CEF With No Leverage
Jul 12HQL: Buy For The Yield, If You Can Stomach The Depreciation
Apr 27Tekla Life Sciences Investors: Buy For Steady, Quarterly Dividend
Feb 11Tekla Life Sciences Investors Rides Biotechnology Wave, Offers Growth With Steady Income
Sep 22Evaluating Closed-End Funds: HQL Is Another Fine Pick In A Hot Sector
Jun 29Tekla Life Sciences Investors: 8% Yield, 7% Discount
Jan 09Tekla Life Sciences declares $0.02 special dividend
Dec 21Tekla Life Sciences declares $0.40 dividend
Nov 16Financial Position Analysis
Short Term Liabilities: HQL's short term assets ($2.7M) do not cover its short term liabilities ($10.0M).
Long Term Liabilities: HQL has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: HQL's net debt to equity ratio (2.2%) is considered satisfactory.
Reducing Debt: HQL's debt to equity ratio has increased from 0% to 2.2% over the past 5 years.
Debt Coverage: Insufficient data to determine if HQL's debt is well covered by operating cash flow.
Interest Coverage: Insufficient data to determine if HQL's interest payments on its debt are well covered by EBIT.